These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22379847)

  • 1. [Comparative analysis of surgical and medical treatment of macroprolactinoma of different localization].
    Astaf'eva LI; Kadashev BA; Dedov II; Kalinin PL; Kutin MA; Shkaburo AN; Fomichev DV; Tenedieva VD; Tropinskaia OF
    Zh Vopr Neirokhir Im N N Burdenko; 2011; 75(4):3-9; discussion 9. PubMed ID: 22379847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
    Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giant prolactinomas: the therapeutic approach.
    Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
    Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of two therapeutic methods for prolactinoma].
    Zhen JR; Yu Q; Zhang YH; Ma WB; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):257-61. PubMed ID: 18843964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giant prolactinomas presenting as skull base tumors.
    Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
    Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
    Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
    Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
    Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
    Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment strategy of pituitary invasive prolactinomas].
    Wu ZB; Yu CJ
    Zhonghua Wai Ke Za Zhi; 2009 Jan; 47(2):123-7. PubMed ID: 19563008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinomas in children and adolescents--consequences in adult life.
    Duntas LH
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1227-32; discussion 1261-2. PubMed ID: 11964017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of hypophyseal prolactin-secreting macroadenomas].
    Candrina R; Tosoni M
    Recenti Prog Med; 1989 Sep; 80(9):471-3. PubMed ID: 2595078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Invasive giant prolactinoma].
    Domínguez Ugidos LJ; Martínez Subías J; Urpegui García A; Sancho Serrano E; Alfonso Collado JI; Vallés Varela H
    Acta Otorrinolaringol Esp; 1998 Mar; 49(2):156-8. PubMed ID: 9650316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactinoma and body weight: a retrospective study.
    Creemers LB; Zelissen PM; van 't Verlaat JW; Koppeschaar HP
    Acta Endocrinol (Copenh); 1991 Oct; 125(4):392-6. PubMed ID: 1957557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactinoma with preferential infrasellar extension: a report of two cases.
    Nishio S; Morioka T; Fujiwara S; Fukui M
    J Clin Neurosci; 2001 May; 8(3):287-9. PubMed ID: 11386812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin-secreting tumors: what's new?
    Molitch ME
    Expert Rev Anticancer Ther; 2006 Sep; 6 Suppl 9():S29-35. PubMed ID: 17004854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The impact of prolactinoma in human reproduction].
    Hurtado Amador R; Ayala AR; Hernández Marín I
    Ginecol Obstet Mex; 2004 Jan; 72(1):3-9. PubMed ID: 15239558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
    Almalki MH; Buhary B; Alzahrani S; Alshahrani F; Alsherbeni S; Alhowsawi G; Aljohani N
    Pituitary; 2015 Jun; 18(3):405-9. PubMed ID: 25062894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy.
    Kim D; Ku CR; Kim K; Jung H; Lee EJ
    Eur J Endocrinol; 2020 Feb; 182(2):177-183. PubMed ID: 31770105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.
    Fleseriu M; Lee M; Pineyro MM; Skugor M; Reddy SK; Siraj ES; Hamrahian AH
    J Neurooncol; 2006 Aug; 79(1):41-3. PubMed ID: 16598425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.